VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 356 filers reported holding VALEANT PHARMACEUTICALS INTL in Q2 2016. The put-call ratio across all filers is 1.00 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $0 | – | 34 | 0.0% | 0.00% | – |
| Q1 2018 | $0 | -100.0% | 34 | -39.3% | 0.00% | – |
| Q4 2017 | $1,000 | – | 56 | 0.0% | 0.00% | – |
| Q3 2017 | $0 | – | 56 | 0.0% | 0.00% | – |
| Q2 2017 | $0 | – | 56 | 0.0% | 0.00% | – |
| Q1 2017 | $0 | – | 56 | 0.0% | 0.00% | – |
| Q4 2016 | $0 | -100.0% | 56 | 0.0% | 0.00% | – |
| Q3 2016 | $1,000 | 0.0% | 56 | 0.0% | 0.00% | – |
| Q2 2016 | $1,000 | -100.0% | 56 | -99.8% | 0.00% | -100.0% |
| Q3 2015 | $5,708,000 | -33.3% | 32,000 | -16.9% | 0.04% | -26.0% |
| Q2 2015 | $8,552,000 | -14.7% | 38,500 | -23.8% | 0.05% | -13.8% |
| Q1 2015 | $10,030,000 | +15.8% | 50,500 | -16.5% | 0.06% | +18.4% |
| Q4 2014 | $8,658,000 | -29.0% | 60,500 | -34.9% | 0.05% | -31.0% |
| Q3 2014 | $12,188,000 | -57.7% | 92,900 | -59.3% | 0.07% | -61.0% |
| Q2 2014 | $28,780,000 | +67.3% | 228,200 | +74.9% | 0.18% | +61.1% |
| Q1 2014 | $17,203,000 | -30.9% | 130,500 | -38.5% | 0.11% | -31.5% |
| Q4 2013 | $24,892,000 | – | 212,031 | – | 0.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 6,050,442 | $763,082,000 | 30.78% |
| LeVasseur Capital Partners LLC | 190,404 | $24,014,000 | 29.50% |
| FARLEY CAPITAL L.P. | 333,081 | $42,008,000 | 27.09% |
| Ruane, Cunniff & Goldfarb | 34,298,384 | $4,325,712,000 | 23.07% |
| ValueAct Holdings | 18,923,877 | $2,386,679,000 | 17.64% |
| Tesuji Partners | 1,368,040 | $172,537,000 | 17.22% |
| Brahman Capital Corp. | 3,902,877 | $492,231,000 | 13.63% |
| Arrow Capital Management, LLC | 197,500 | $24,909,000 | 13.60% |
| Hound Partners | 2,851,175 | $359,590,000 | 13.45% |
| Ratan Capital Management LP | 731,960 | $92,315,000 | 13.09% |